# Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder

> **NCT00151450** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 390 (—)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Pregabalin
- **DRUG:** Venlafaxine XR

## Key facts

- **NCT ID:** NCT00151450
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 390 (—)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151450, "Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00151450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*